Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
President Trump. Photo: Mandel Ngan / Getty Images
White House physician Sean Conley issued a statement Friday detailing the type of coronavirus test that President Trump took before receiving a positive result, as well as his current COVID-19 treatment.
Why it matters: Trump, who is reportedly experiencing "mild" symptoms, is at higher risk for a severe COVID-19 infection due to his age and body mass index.
What they're saying: "Following PCR-confirmation of the President's diagnosis, as a precautionary measure he received a single 8 gram dose of Regeneron's polyclonal antibody cocktail," Conley said.
- "He completed the infusion without incident. In addition to the polyclonal antibodies, the President has been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin."
- Trump is "fatigued but in good spirits," Conley said, while the first lady has "a mild cough and headache."
Zoom in: Regeneron Pharmaceuticals announced earlier this week that its coronavirus antibody cocktail reduced viral load for patients enrolled in early and late-stage trials — which are ongoing.
- The company gave Trump the cocktail — which is not yet approved by the FDA —through a compassionate use request, since the drug is still being evaluated for its safety and efficacy in tests with hospitalized and non-hospitalized patients, Regeneron said in a Friday press release.
- Regeneron defines its compassionate use program as "intended for patients with serious or life-threatening conditions who do not have any viable or available treatment options, and are unable to participate in ongoing clinical trials."